Philippe Monteyne

The HealthTech For Care endowment fund has three essential missions: - fostering the growth and development of the entire health ecosystem, - advocating for the advancement of innovative therapies and treatments to benefit patients, - promoting enhanced access to care for patients within the European healthcare ecosystem.

Sagitta Biotech is a company developping an innovative viral vector to develop efficient vaccines, oncolytic viruses and gene therapy vectors. Our active virosome platform can deliver up to 17kb mRNA (6 genes), and elicit both humoral and cellular reponse. Sagitta is developping its own pipeline of innovative multivalent vaccines (currently in preclinical phases) and oncolytic viruses, and is open to partnering and co-development. In ancient Greece, Sagitta was regarded as the weapon that Hercules used to kill the eagle (Aquila) of Jove that perpetually gnawed Prometheus​ liver.

Ona Therapeutics is pioneering the development of first-in-class antibody drug conjugates (ADCs) that exploit the molecular underpinnings of advanced cancer. We partner with renowned academics and clinicians to discover novel therapeutic targets from the unique biology of treatment refractory advanced cancer patients. Our approach combines privileged biology with Ona’s expertise in biologics. Together, we craft ADCs and antibody therapies, aiming to provide effective new treatments for patients with no remaining alternatives.

Egle Therapeutics has been founded with a vision to become a game changer in the field of immunomodulating T-regulatory cells (Tregs) through the unique concept of Tregs’ starving while specifically targeting the most immunosuppressive ones.

Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million

Op2Lysis develops new treatments for patients suffering from thrombosis at the cerebrovascular level, with an initial focus on the hemorrhagic form of stroke. Indeed, there is no currently approved and available therapeutic solution for these patients. The company develops its game-changing NANOp2Lysis platform, associating a breakthrough vectorisation technology, industrial know-how enabling clinical quality production, and preclinical expertise to propose predictive and translational models, a first in this field. O2L-001, the first product resulting from this technology, will soon enter regulatory toxicology with the aim of applying for clinical trial authorisation in patients in North America and Europe.

Coave Therapeutics is a clinical stage biotechnology company focused on developing life changing gene therapies in rare Ocular and CNS (Central Nervous System) diseases. We are pushing the boundaries of gene therapy through application of our AAV-Ligand Conjugates platform (ALIGATER) that enables targeted delivery, enhanced gene transduction and tissue distribution to improve the effectiveness of advanced gene therapies for rare diseases. Our strategy is to advance a pipeline of novel therapies targeting rare ocular and CNS diseases where targeted gene therapy has the potential to be most effective, where there is a clear unmet need and where success will provide rapid validation of our ALIGATER platform.

AELIX Therapeutics is a clinical-stage biotechnology company based in Barcelona, Spain. It is focused on the development of a therapeutic HIV vaccine to be included in cure/eradication strategies. AELIX Therapeutics is a spin-off of HIVACAT, the Catalan public-private consortium conducting cutting-edge research in this field. AELIX holds a worldwide, exclusive license for the development and commercialization of the HTI immunogen.

Driving discovery and solving challenges for partners across LNP formulation and RNA chemistry | www.etherna.be | www.ethernamanufacturing.com We are an RNA technology company, with over 30 years’ experience, offering professional partnership to pharma and biotech with an emerging or established interest in RNA therapeutics. Our expert team supports start-up, early stage and late stage projects by using our proprietary platforms across RNA chemistry, LNP formulation and Process Technology, to drive new pipeline development or resolve manufacturing challenges for our partners.

Ogeda SA is a pharmaceuticals company based out of Route de Lennik 802, Brussels, Belgium.

Novadip Biosciences is a clinical-stage biopharmaceutical company founded to design, develop, and bring to the market a new class of regenerative tissue products to accelerate healing of large bone defects and injuries in a single treatment. Novadip’s lead allogeneic product, NVD-X3, employs a matrix containing multiple bioactive factors that induce accelerated tissue healing. Designed as an “off-the-shelf” product, NVD-X3 can be shipped and stored at room temperature and offers superior intraoperative handling characteristics. Novadip is also developing NVD-003, an autologous therapy derived from ASCs as a potential single treatment to save limbs and restore mobility in patients with congenital pseudarthrosis of the tibia (CPT). CPT is a rare pediatric bone condition. Learn more about our technology platform and clinical development programs at www.novadip.com Phone number: +32/10 77 92 20 E-mail: info@novadip.com VAT: BE0535.575.602 Privacy policy: https://novadip.com/privacy-policy/

Le Leem, Les Entreprises du médicament, regroupe les entreprises du secteur de l'industrie pharmaceutique en France. Créé il y a plus de 130 ans, le Leem compte aujourd’hui près de 270 entreprises adhérentes, qui réalisent près de 98 % du chiffre d’affaires total du médicament en France. L’industrie pharmaceutique emploie 100 000 personnes dans plus de 150 métiers, et recrute 10 000 collaborateurs par an depuis 10 ans. Chaque année, l’industrie pharmaceutique investit 12 % de son chiffre d’affaires dans la recherche, afin de mettre au point de nouveaux traitements innovants. Elle rassemble plus de 20 000 personnes dans ses centres de R&D, qui font de la France un pays phare dans les sciences de la vie et participent à l’indépendance sanitaire du pays. Les entreprises du médicament ont en effet pour mission de créer et de développer des médicaments et vaccins nouveaux à usage humain, pour les maladies graves comme pour les maladies "​ sociétales "​ liées au bien-être et aux pathologies du quotidien. Le rôle du Leem consiste à faciliter les échanges entre ses membres, à défendre leurs intérêts collectifs et à resserrer les liens avec les autres professions de santé. Parmi les missions du Leem, figure l’élaboration et le respect de la déontologie des pratiques professionnelles de l’industrie pharmaceutique. Elle s’assure donc du bon respect des règles d’éthique de la profession et de la conformité des entreprises du médicament aux dispositions des codes de bonne conduite.

BIOASTER Technology Research Institute (TRI) is working to develop an unique technological and innovative model to support the latest challenges in microbiology, in particular to : -Fight antimicrobials resistance. -Improve vaccines safety and efficacy. -Quickly diagnose infections at patient bedside. -take full advantage to human and animal microbiota. In order to overcome technological bottlenecks and explore new avenues, BIOASTER is leading collaborative projects that bring together academics, start-ups, SMEs and industrial groups around key thematic and technology units. Each project strives on academic research excellence and is undertaken by a team of high-level experts and engineers, which benefits from state-of-the-art equipment, technological infrastructures. BIOASTER, an independent non-profit organization, is one of 8 French TRIs created in 2012 on the initiative of the French Government through the “Investments for the Future” program. The two historical founders are Lyonbiopôle (a biocluster, the one-stop shop for healthcare innovation in Rhône-Alpes, France) and the Institut Pasteur in Paris. They were joined from the beginning by the CNRS, the INSERM, the CEA, Mérieux Institute, Danone Nutricia Research and Sanofi Pasteur -and newly joined by bioMérieux- to create a unique Technology Institute dedicated to infectious diseases and microbiology in health. The Institute benefits from the support of Lyon Métropole and the Region Auvergne Rhône Alpes and the dynamism of a group of 40 SMEs in the Lyon and Paris regions. Located in Lyon and Paris, BIOASTER has more than 100 employees including 80 world-class scientists and engineers originating from 16 different countries. More information on www.bioaster.org

Innesto Partners is a European focused fund investing in search funds and operating companies. Through the search fund model, Innesto Partners enables motivated entrepreneurs to search, buy, and operate a private, profitable, small business while solving succession issues for its owner. Such an entrepreneur is referred to as a “searcher,” and the vehicle used as a “search fund”. A searcher is someone relatively young but qualified to buy and run a small business. Typically, an MBA graduate with consulting, investment banking, VC/PE, and/or elevated operational work experience. Target industries are typically fragmented, growing and sizeable, and have straightforward operations which are easy to learn. Target companies typically have a clear competitive advantage, recurring and predictable revenues, >10% EBITDA margins, multiple avenues for growth, solid middle management, available financing, owners motivated to sell for non-business reasons, reasonable valuation expectations, and realistic liquidity options in the medium term. Innesto Partners have been in the searchers’ shoes as our team consists of ex-searchers, operators and financiers.

AltamarCAM is a leading investment manager in private markets whose main objective is to provide institutional investors, including insurance companies, pension funds and financial institutions, as well as high net worth private clients, with access to investments in unlisted markets: private equity, venture capital, life sciences, real assets (real estate and infrastructure) and private debt / credit, through a selection international managers and in different strategies (primaries, secondaries and co-investments). In addition, AltamarCAM provides independent investment banking services (advice on mergers and acquisitions, IPOs and financing) and merchant banking through its subsidiary Altamar Advisory Partners, as well as direct access to funds from a selection of international managers through its subsidiary Altamar Global Investments AV. With offices in Madrid, Barcelona, Santiago de Chile, New York, London, Cologne and Munich, it has a team of more than 250 professionals. AltamarCAM has ca. 17,9 billion euros in assets committed by investors.

The HealthTech For Care endowment fund has three essential missions: - fostering the growth and development of the entire health ecosystem, - advocating for the advancement of innovative therapies and treatments to benefit patients, - promoting enhanced access to care for patients within the European healthcare ecosystem.

Sagitta Biotech is a company developping an innovative viral vector to develop efficient vaccines, oncolytic viruses and gene therapy vectors. Our active virosome platform can deliver up to 17kb mRNA (6 genes), and elicit both humoral and cellular reponse. Sagitta is developping its own pipeline of innovative multivalent vaccines (currently in preclinical phases) and oncolytic viruses, and is open to partnering and co-development. In ancient Greece, Sagitta was regarded as the weapon that Hercules used to kill the eagle (Aquila) of Jove that perpetually gnawed Prometheus​ liver.

Aliath Bioventures is a life sciences venture investor and advisor to AltamarCAM specialized in life sciences and healthcare markets.